AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

"attachment_1199068" align="aligncenter" width="1456"] A pharmacy worker distributing prescription medicines to ...

AstraZeneca has increased its investment in U.S. operations more than 14-fold, committing $50 billion to a range of ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy targets.

President Donald Trump referenced the announcement the following day in Oval Office remarks, framing AstraZeneca’s overall ...

AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030.